following are of us antibody excited for of US we launch the offers XXXX. a thanks We BRIUMVI’s approved in today's for share can all of multiple infusion starting the sclerosis, treatment potential and approval and that to clinical are a patients, able in offer exciting that forms excellent for we partial commercial of XXXX quarter of to administered commencing first has start to us patients and key and to on XX, profile Jenna, relapsing twice value good morning, monoclonal proposition results BRIUMVI, TG, call. be anti-CDXX at best-in-class with pleased providers, is and the one-hour on payers. everyone, believe including an constituents, and January off joining and the our first an Thanks, for be Today, sales MS the only year dose.
As essentially of the such, are availability. months commercial first we BRIUMVI two on reporting
launch metrics Officer, the Commercialization my Chief of will Accordingly, comments us will the regarding other high interest touch first provide level, results. some surrounding a may a join be on investors. Our shortly few keep and that to Adam Waldman, I detailed quarter at to topics
to by Geographically, are the With profile Early adoption nice from have our our the said we see respect through enthusiasm such BRIUMVI the we to launch, providers, has for that and to some received been well pleased time carrying have come healthcare community and phase. have accounts. launch within territories major adoption target HCPs we seen BRIUMVI, practices. all has centers and academic prescribing both seen of of
pleased as launch and medical a attributes teams are with and switches we which introducing I'm access, building Overall, BRIUMVI, thus to, educating the I doing commercial new those and also are also that from In fantastic of CDXXs, believe and other very job believe to of terms further BRIUMVI the underscores the of the a healthcare distribution well providers treatment, are teams to of patients, our CDXX we on, nice BRIUMVI treatment, as new attractiveness seeing far. profile. MS payer
the patients I and about the by announced to such recommending opinion, the the on by treatment application, end month the want a our of as opinion features. BRIUMVI EMA, March, With that or and disease plans. a decision of ago, With issued launch active of June. adult talk from European the final Medicines with Use for that, At approval marketing hear Committee to about briefly for our move imaging authorization clinical the Human positive Products Agency, for expect we of defined this RMS we ex-US European EMA I'll Medicinal a early
evaluate another alone answer coming later opportunity We to we see that a go the if additional as commercial BRIUMVI Europe, to Whatever it best months Europe launch pathway making either continue shareholder in to value by for enable year, us pathway approved. available create we question internationally. we partner, the seek European to or will in and this select,
Finally, cash let me discuss position. TG's
As we in million Hercules $XXX us $XX the include capacity quarter of to reported, when you ended with under our approximately the million cash, available facility. additional
assumptions current capacity, modest to be revenue, our believe with us incremental mid-XXXX. Hercules associated and We sufficient cash along of into will take continue to
our should stable current revenues is With course, ways. continue sheet to current model, need how much, clear dilutive and not last burn, our to or position adding in our those for breakeven. any, many balance in non-dilutive comfortable the it minimally if Of would we our revenues amounts to growing raise if longer Accordingly, to cash even we cash exceed cash our are options and relatively prior cashflow quite with with
to to our that, on Chief Waldman, share call over launch. additional some With me Commercialization turn Adam? color our quarter let of Officer, first Adam the
